JP2022512851A - がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン - Google Patents

がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン Download PDF

Info

Publication number
JP2022512851A
JP2022512851A JP2021523335A JP2021523335A JP2022512851A JP 2022512851 A JP2022512851 A JP 2022512851A JP 2021523335 A JP2021523335 A JP 2021523335A JP 2021523335 A JP2021523335 A JP 2021523335A JP 2022512851 A JP2022512851 A JP 2022512851A
Authority
JP
Japan
Prior art keywords
antibody
heavy chain
light chain
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523335A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020096915A5 (https=
JP2022512851A5 (https=
Inventor
ツァイ，ミンメイ
チャータッシュ，エリオット・ケー
ヒーリー，ジェーン・アン
ララ，マリカ
リー，トミー・ルオシ
マヤワラ，カピル
プレドユ，ラルカ・アンドレイ
ウィリアムズ，シビル・エム・ジー
ゾン，ジェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2022512851A publication Critical patent/JP2022512851A/ja
Publication of JPWO2020096915A5 publication Critical patent/JPWO2020096915A5/ja
Publication of JP2022512851A5 publication Critical patent/JP2022512851A5/ja
Priority to JP2024178276A priority Critical patent/JP2025004212A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2021523335A 2018-11-05 2019-11-04 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン Pending JP2022512851A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024178276A JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024178276A Division JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Publications (3)

Publication Number Publication Date
JP2022512851A true JP2022512851A (ja) 2022-02-07
JPWO2020096915A5 JPWO2020096915A5 (https=) 2022-11-16
JP2022512851A5 JP2022512851A5 (https=) 2022-11-16

Family

ID=70611082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523335A Pending JP2022512851A (ja) 2018-11-05 2019-11-04 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Country Status (10)

Country Link
US (1) US20210403557A1 (https=)
EP (1) EP3877418A4 (https=)
JP (2) JP2022512851A (https=)
KR (1) KR20210091209A (https=)
CN (1) CN113302204A (https=)
AU (1) AU2019375409A1 (https=)
BR (1) BR112021008582A8 (https=)
CA (1) CA3118964A1 (https=)
MX (1) MX2021005236A (https=)
WO (1) WO2020096915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3208612B1 (en) 2008-04-09 2019-09-18 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CN115916348A (zh) * 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
US20240262915A1 (en) * 2020-09-22 2024-08-08 Nanjing Sanhome Pharmaceutical Co., Ltd. Anti-tigit antibody and double antibody and their application
EP4384550A4 (en) * 2021-08-10 2025-06-18 Merck Sharp & Dohme LLC THERAPEUTIC COMBINATION WITH A TIGIT ANTAGONIST, A PD-1 ANTAGONIST AND LENVATINIB
KR20240047393A (ko) * 2021-08-10 2024-04-12 머크 샤프 앤드 돔 엘엘씨 Tigit 길항제, pd-1 길항제 및 화학요법제(들)를 포함하는 치료 조합물
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532007A (ja) * 2014-08-19 2017-11-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｔｉｇｉｔ抗体
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968488A1 (en) * 2013-03-15 2016-01-20 Amgen Inc. Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CN107207594B (zh) * 2014-12-23 2019-05-07 百时美施贵宝公司 针对tigit的抗体
TN2017000440A1 (en) * 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CA2994858C (en) * 2015-09-25 2024-01-23 Genentech, Inc. Anti-tigit antibodies and methods of use
SMT202300418T1 (it) * 2017-05-30 2024-01-10 Bristol Myers Squibb Co Trattamento di tumori positivi per lag-3
WO2019152574A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017532007A (ja) * 2014-08-19 2017-11-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｔｉｇｉｔ抗体
WO2017202744A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY, vol. 7, JPN6023048831, 24 May 2018 (2018-05-24), pages 8 - 1466769, ISSN: 0005467336 *
THE LANCET ONCOLOGY, vol. Volume 17, Issue 11, JPN6023048830, 2016, pages 1497 - 1508, ISSN: 0005467337 *

Also Published As

Publication number Publication date
CA3118964A1 (en) 2020-05-14
WO2020096915A1 (en) 2020-05-14
BR112021008582A8 (pt) 2023-02-07
EP3877418A4 (en) 2022-08-17
JP2025004212A (ja) 2025-01-14
US20210403557A1 (en) 2021-12-30
KR20210091209A (ko) 2021-07-21
EP3877418A1 (en) 2021-09-15
MX2021005236A (es) 2021-06-18
CN113302204A (zh) 2021-08-24
AU2019375409A1 (en) 2021-05-27
BR112021008582A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
JP7507209B2 (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
JP6894952B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
CN105451770B (zh) 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
JP6783312B2 (ja) がんを処置するためのｏｘ４０アゴニストおよび４−１ｂｂアゴニストモノクローナル抗体の組み合わせ
JP2022512851A (ja) がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
JP7470105B2 (ja) 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
JP2022512866A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
JP2024513247A (ja) 抗ｐｄ－１抗体の皮下投与によるがんの治療方法
JP2023543978A (ja) がん患者を治療するためのｐｄ－１拮抗薬及びｌａｇ３拮抗薬及びレンバチニブ又はそれの薬学的に許容される塩の併用療法
RU2833669C2 (ru) Режим введения антитела к tigit для лечения рака
WO2025128499A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241010

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241121

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20241129